IP Verse

Schering competitive analysis

Latest patents of Schering opposed by its competitors

Explore Schering's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 3, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP1819323
Mar 22, 2023Pharmaceutical Composition Containing An Anti-Nucleating Agent2
EP2399588
Apr 29, 2020Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral Polymerase1
EP1747001
Oct 10, 2018Management Of Breakthrough Bleeding In Extended Hormonal Contraceptive Regimens4
EP2475388
Nov 8, 2017Use Of Il-33 Antagonists To Treat Fibrotic Disease1
EP1931710
Jan 18, 2017Engineered Anti-Il-23 Antibodies3
EP2004646
Jun 8, 2016Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One And Preparation Process Therefor1
EP1855674
Jul 16, 2014Composition For Inhibition Of Cathepsin K2

Latest PTAB cases involving Schering

Discover the latest PTAB cases involving Schering, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Schering with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
SCHERING - 14 - -
ABBVIE1214 - 1
ABBVIE OVERSEAS RL1 - - -
ELI LILLY18331715